Bone Biologics
BBLG
3 hedge funds and large institutions have $20.8K invested in Bone Biologics in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.28% less ownership
Funds ownership: 0.41% → 0.13% (-0.28%)
50% less funds holding
Funds holding: 6 → 3 (-3)
63% less capital invested
Capital invested by funds: $55.8K → $20.8K (-$35K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.55K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$6 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$20.6K |
| 2 |
HF
HRT Financial
New York
|
-$13K |
| 3 |
Citigroup
New York
|
-$4.65K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.51K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $19.4K | +$8.55K | +1,475 | +58% |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $1.46K | -$1.51K | -261 | -46% |
|
|
3
Bank of America
Charlotte,
North Carolina
| $17 | +$6 | +1 | +33% |
|
|
SS
4
SBI Securities
Tokyo,
Japan
| $1 | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| – | -$20.6K | -3,644 | Closed |
|
|
HF
6
HRT Financial
New York
| – | -$13K | -2,443 | Closed |
|
|
7
Citigroup
New York
| – | -$4.65K | -825 | Closed |
|
BBLG Hedge Fund Activity: Q1 2025 in Review
3 of the 7,460 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics (BBLG) for Q1 2025, worth a combined $20.8K — down 63% from $55.8K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BBLG and 0 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Geode Capital Management, adding an estimated $8.55K. The largest seller was UBS Group, exiting entirely with an estimated $20.6K sold.
- 3 institutional investors held Bone Biologics (BBLG) as of Q1 2025, down from 6 in Q4 2024.
- Funds reported $20.8K of Bone Biologics stock for Q1 2025, down 63% quarter-over-quarter.
- 0 funds opened new Bone Biologics positions in Q1 2025 and 3 closed out, a net change of -3 holders.
- The largest Bone Biologics buyer in Q1 2025 was Geode Capital Management, an estimated $8.55K added.
- The largest Bone Biologics seller in Q1 2025 was UBS Group, an estimated $20.6K sold.
Based on aggregated 13F filings for Q1 2025.